Moderna Shares Rise 12% June 26, Up 125.51% Since January
2026-06-29 07:58:41
Moderna (NASDAQ: MRNA) shares closed up 12% on Friday, June 26, extending gains to 125.51% since January. The rally follows an FDA Vaccines and Related Biological Products Advisory Committee 9-0 vote on June 18 that mFLUSIVA (mRNA-1010) has a favorable benefit-risk profile for adults 50 and older, according to BeInCrypto, ahead of an Aug. 5 PDUFA decision date. Piper Sandler lifted its price target to $77 and Jefferies raised its target to $53 while keeping a Hold rating; the consensus target is $43.45. Moderna also restructured around vaccines, oncology and rare diseases and highlighted its pipeline at a June 25 Science Day.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
Moody’s Says India Can Withstand Modest Fiscal Slippage This YearNext article：
今日恐慌与贪婪指数为16，等级为极度恐慌
